OmniAb Inc. Total Liabilities
OmniAb Inc. total liabilities. Based on the latest financial reports, OmniAb Inc. (OABI) has total liabilities worth $29.98 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OmniAb Inc. (OABI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of OmniAb Inc. (2019–2025)
Total liabilities of OmniAb Inc. from 2019 to 2025. This chart illustrates how OmniAb Inc.'s total liabilities have evolved over time, based on quarterly financial data.
OmniAb Inc. Competitors by Total Liabilities
The table below lists competitors of OmniAb Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qingdao Hiron Commercial Cold Chain Co Ltd
SHG:603187
|
China | CN¥1.98 Billion |
|
Autohellas S.A.
AT:OTOEL
|
Greece | €1.20 Billion |
|
Haier Smart Home Co Ltd
XETRA:690D
|
Germany | €164.14 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
Sweden | Skr3.89 Trillion |
|
Fundamenta Real Estate AG
SW:FREN
|
Switzerland | CHF711.28 Million |
|
Kangping Technology (Suzhou) Co. Ltd.
SHE:300907
|
China | CN¥1.97 Billion |
|
Energy Resources of Australia Ltd
AU:ERA
|
Australia | AU$2.34 Billion |
|
Bright Oceans Inter Telecom Corp
SHG:600289
|
China | CN¥617.06 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down OmniAb Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OABI current and non-current assets.
Liquidity & Leverage Metrics
OmniAb Inc. Total Liabilities Ratios Explained
OmniAb Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OmniAb Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OmniAb Inc. (2019–2025)
The table below shows the annual total liabilities of OmniAb Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.89 Million | -10.68% |
| 2024-12-31 | $37.94 Million | -37.43% |
| 2023-12-31 | $60.64 Million | -24.05% |
| 2022-12-31 | $79.84 Million | +13.80% |
| 2021-12-31 | $70.16 Million | +17.24% |
| 2020-12-31 | $59.84 Million | +35.59% |
| 2019-12-31 | $44.13 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more